TRAIL R2 Multimeric Scaffolds for Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody-based therapeutic approaches for targeting TRAIL R2 receptors are limited by the short lifespan of TRAIL and the large size of antibodies, which impede tumor penetration and stability, necessitating the development of novel molecules with improved binding affinity and stability for cancer treatment.
Innovation Solution
A TRAIL R2-specific recombinant multimeric scaffold comprising multiple Tn3 monomers connected by linkers, specifically designed to enhance binding affinity and stability, allowing for improved interaction with TRAIL R2 receptors and potential use in cancer therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If classical antibodies are used to target TRAIL R2 receptors, then binding affinity can be achieved, but the large size of antibodies limits tumor penetration and they require complex mammalian cell expression systems
Solution Approach 1:
The patent extracts only the essential binding function from full-length antibodies by using antibody fragments (such as scFv, Fab, or single-domain antibodies) that retain TRAIL R2 binding capability but lack the bulky constant regions and Fc portions, thereby reducing molecular size while preserving binding affinity
Solution Approach 2:
The patent creates simplified copies of antibody binding functionality using alternative protein scaffolds (such as camelid VHH domains, nanobodies, or engineered protein domains) that can bind TRAIL R2 with high affinity but have fundamentally different, more compact structures than conventional antibodies
2Reliability
If TRAIL is used as a therapeutic agent, then apoptosis induction in tumor cells can be achieved, but TRAIL has a very short lifespan and binds to decoy receptors
Solution Approach 1:
The patent uses engineered binding proteins as intermediaries that specifically recognize and bind TRAIL R2 receptors on tumor cells, thereby mediating the apoptotic signal without requiring the direct delivery of TRAIL itself, which has short lifespan and binds to decoy receptors
Solution Approach 2:
The patent modifies the molecular parameters of the therapeutic agent by creating engineered proteins with altered stability characteristics, extended half-life through PEGylation or fusion to albumin-binding domains, and enhanced specificity through affinity maturation, thereby improving duration of action while maintaining apoptosis induction capability
3Weight of moving object
If antibody fragments are used to reduce size, then tumor penetration can be improved, but they tend to aggregate and are less stable than full-length IgGs
Solution Approach 1:
The patent employs disposable, single-use antibody fragments or nanobodies that are designed to be administered at higher doses with frequent dosing schedules, accepting their shorter in vivo half-life in exchange for their small size and reduced aggregation, while maintaining therapeutic efficacy
Solution Approach 2:
The patent creates composite molecular structures by fusing antibody fragments with stabilizing elements such as Fc domains (to form half-antibodies), PEG chains, or albumin-binding modules, thereby combining the small size advantage of fragments with the stability and solubility benefits of larger structures
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention provides Tenascin-3 FnIII domain-based multimeric scaffolds that specifically bind to TRAIL Receptor 2 (TRAIL R2), a cell membrane receptor involved in apoptosis. The invention further provides engineered variants with increased affinity for the target, increase stability, and reduced immunogenicity. Furthermore, the present invention is related to engineered multivalent scaffolds as prophylactic, diagnostic, or therapeutic agents, and their uses against diseases caused by cells expressing TRAIL R2, in particular to a therapeutic use against cancer.